Mineralys Operating Income from 2010 to 2026

MLYS Stock   30.89  1.20  3.74%   
Mineralys Therapeutics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2026. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Mineralys Therapeutics Common generates from its operations. View All Fundamentals
 
Operating Income  
First Reported
2010-12-31
Previous Quarter
-173.2 M
Current Value
-164.5 M
Quarterly Volatility
68 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Mineralys Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 17.6 M, Depreciation And Amortization of 36.8 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.95. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Mineralys Stock
Check out the analysis of Mineralys Therapeutics Correlation against competitors.
The evolution of Operating Income for Mineralys Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Mineralys Therapeutics compares to historical norms and industry peers.

Latest Mineralys Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Mineralys Therapeutics Common over the last few years. Operating Income is the amount of profit realized from Mineralys Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Mineralys Therapeutics Common is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Mineralys Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Income10 Years Trend
Slightly volatile
   Operating Income   
       Timeline  

Mineralys Operating Income Regression Statistics

Arithmetic Mean(41,017,898)
Coefficient Of Variation(165.88)
Mean Deviation53,018,314
Median(2,943,000)
Standard Deviation68,038,439
Sample Variance4629.2T
Range189.5M
R-Value(0.76)
Mean Square Error2068T
R-Squared0.58
Significance0.0004
Slope(10,271,692)
Total Sum of Squares74067.7T

Mineralys Operating Income History

2026-164.5 M
2025-173.2 M
2024-192.4 M
2023-84.7 M
2022-31.5 M
2021-18.7 M

About Mineralys Therapeutics Financial Statements

Mineralys Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Income-173.2 M-164.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Mineralys Stock Analysis

When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.